Cannabis Related Content

Here, Professor Mike Barnes discusses and answers some key questions about the world of CBD in the UK.

Renata Mala, PharmD, Chairman of Purely Plant GmbH, underlines the importance of ensuring high and reproducible quality when it comes to medicinal cannabis.

Here, we learn how Mile High Labs, a leading processor of hemp-derived cannabinoids, have raised Series B equity financing and are preparing for global CPG partnerships.

Kathleen Denoodt continues to enlighten us on the subject of medical cannabis, particularly imports to Germany and the Netherlands.

A new public health app by DRUID® measures factors to give an overall score of impairment, evolving the classic idea of drug testing.

Associate, David Hardstaff and Partner, John Binns at BCL Solicitors LLP, explain here how cannabis wonder child takes a knock in light of the European Commission’s ‘pause’ on CBD novel food applications mean for this booming industry.

Janosch Kratz discusses the importance of medical cannabis for chronic pain diseases.

Chair of the European Medicinal Cannabis Association (EUMCA) issues warning that raising limit for THC in CBD to 0.3% will risk patient safety.

Dr David Moorhouse, General Neurologist, discusses the way that different diseases respond to different types of medical cannabis.

Dr Daniela Tonucci, a consultant for over 10 years, talks us through the use of cannabinoids as pain medicine.

Professor Trevor Jones, Chair at the European Medicinal Cannabis Association, speaks to Nishat about their plans for EU patient access to medicinal cannabis.

David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health, discusses new funding opportunities for cannabinoid research.

Here, we learn how about a different kind of green crop that grows in Ireland and the journey of that from seed to shelf as part of the Greenheart CBD story.

In the last six months GreenLight Medicines has successfully out-licenced leads from its research, branching out internationally and attracting major investors.

In this interview, David Engel from Full Moon Investments in the U.S., charts the firm’s successful targeted investment strategy – informed by industry-leading experience and expertise – including comments on the CBD hemp and medical cannabis space.

Elixinol has launched a new UK range of blended, full-spectrum CBD capsules using six original combinations developed to support good health and wellbeing.

Dr Christian Löfke, responsible for research and product development at BioBloom, walks us through the rudiments of essential oils as a potential modulator of the endocannabinoid system.

Kathleen Denoodt shares with us what we need to know about the export of medicinal cannabis from Israel.

In this final article of a series of five, Oxford Cannabinoid Technologies will discuss their expertise on the use of cannabinoids in medicine when it comes to treating COVID-19.

Here, CBDepot discuss how they worked with the European Commission to achieve a “valid” Novel Food Application.